https://twitter.com/pc_432/status/1338265436685680642
https://nitter.net/pc_432/status/1338265436685680642
http://www.china.org.cn/china/special_coverage/2018-12/19/content_74290838.htm
https://twitter.com/mista98berk/status/1725991330239672797
https://nitter.net/mista98berk/status/1725991330239672797
Stéphane Bancel, CEO of Moderna, was previously CEO of Bio-Mérieux whose owner, Alain Mérieux, friend of Xi Jinping, financed the P4 laboratory in Wuhan.
https://twitter.com/JordanSchachtel/status/1397253077464461316
https://nitter.net/JordanSchachtel/status/1397253077464461316
(for more links read the full thread)
File this under shocking connections worth further exploration: Moderna CEO Stéphane Bancel (now a billionaire equity shareholder) was previously CEO of bioMérieux. bioMérieux's founder, Alain Mérieux, is a personal friend of Xi Jinping, & he helped build the P4 lab in Wuhan.
Moderna also happened to have a vaccine ready to go within hours of China publicizing gene sequence for virus. Recall, the bio tech company had ZERO products brought to market prior to its "miracle" mRNA vax receiving emergency approval.
Prior to mRNA vax, Moderna was on its way to becoming the next Theranos. They had billions of $$$ in fundraising thanks to hype, but no functioning products. We are now supposed to believe they solved it in a matter of hours, after a decade of failures.
Even after leaving for Moderna, Bancel continued to serve on the board for Foundation Merieux, the non-profit affiliated with the company.
https://christopherfalcon.substack.com/p/the-french-connection-from-the-wuhan
In 2004 the Chinese contacted the French company bioMerieux owned by Alain Merieux, (who is a personal friend of now dictator Xi Jinping) to design a level 4 bio facility in Wuhan, China as the Chinese had limited experience in designing a level 4 facility. This facility would take a full ten years to come to fruition, but during that time, the now CEO of Moderna was formerly the CEO of bioMerieux (2007-2011) through which time he overseen the design of the now infamous Wuhan lab. It was revealed in August of 2021 that The Wuhan lab had serious ventilation issues as described in the House Foreign Affairs Committee Origins of Covid Report. In September of 2019 the WIV took its virus database off the internet, not long after that the WIV had a contract competition to renovate its air conditioning/ventilation system. The contract ended up being for a total of $606 million, evidence of which the Chinese Ministry of Finance later pulled according to WaPo journalist Josh Rogin. The WIV level 4 lab was inaugurated on January 31, 2015, after being designed by the aforementioned French company, and was built by the Chinese end of that partnership. The question is this: did the Chinese know the French designed a horribly flawed ventilation system that bioMerieux also apparently never finished, or were they just as surprised as the rest of the world? Since the Chinese CDC was at Event 201, it’s hard to say for certain.
Considering that Stephane Bancel, one of the main people involved in the design of the WIV lvl4 lab left the company some three years before the actual construction of the lab does give him some plausible deniability… that is until you think about if for more than thirty seconds. What is the likelihood of Bancel overseeing the design of the WIV level 4 lab, then, leaving bioMerieux to become the CEO of the mRna vaccine company Moderna?
Moderna was perfectly positioned to make billions of dollars through global emergency use authorizations after this illegally U.S. government funded (through Echo Health alliance via NIAID and Fauci according to DARPA documents obtained via a FOIA request) Gain of Function research created the Chimera spike protein which was inserted into the backbone of a Sars Cov virus. Which is why the French, nor the Americans would even entertain the idea of a lab leak, even though they all knew once the scientific community figured out the covid19 genetic sequence. A Novel virus, indeed.
The strange saga of how France helped build Wuhan's top-security virus lab - The maximum-level biosafety laboratory at the Wuhan Institute of Virology was the first of its kind to be built in China, and has been the centre of huge speculation since the start of the Covid-19 pandemic which originated in that city.
The laboratory, which is equipped to handle Class 4 pathogens (P4) including dangerous viruses such as Ebola, was built with the help of French experts and under the guidance of French billionaire businessman Alain Mérieux, despite strong objections by health and defence officials in Paris.
Since the laboratory's inauguration by prime minister Bernard Cazeneuve in 2017, however, France has had no supervisory role in the running of the facility and planned cooperation between French researchers and the laboratory has come to a grinding halt.
But as more trials get underway, Moderna is gingerly opening up. The company agreed to Science's request for access to some of its researchers and labs over the past few months. And last month, at the annual J.P. Morgan Healthcare Conference in San Francisco, California, CEO Stéphane Bancel unveiled Moderna's first round of drug candidates, which include vaccines for Zika and flu, and a therapy for heart failure.
Expectations are high. Being a startup valued at more than a billion dollars—an anomaly that venture capitalists dub a unicorn—comes with scrutiny, and many wonder whether Moderna's pipeline, consisting mostly of vaccines for now, will expand to match the company's original vision of mRNA as a broad treatment platform. "There were a lot of really big promises made," says Jason Schrum, a biotechnology consultant in San Francisco and a former Moderna employee. "That's what people latched onto; they want the promises to be true, and they want to see the investment really turn it into something meaningful."
https://twitter.com/pc_432/status/1338265436685680642
https://nitter.net/pc_432/status/1338265436685680642
http://www.china.org.cn/china/special_coverage/2018-12/19/content_74290838.htm
https://twitter.com/mista98berk/status/1725991330239672797
https://nitter.net/mista98berk/status/1725991330239672797
Stéphane Bancel, CEO of Moderna, was previously CEO of Bio-Mérieux whose owner, Alain Mérieux, friend of Xi Jinping, financed the P4 laboratory in Wuhan.
https://twitter.com/JordanSchachtel/status/1397253077464461316
https://nitter.net/JordanSchachtel/status/1397253077464461316
(for more links read the full thread)
File this under shocking connections worth further exploration: Moderna CEO Stéphane Bancel (now a billionaire equity shareholder) was previously CEO of bioMérieux. bioMérieux's founder, Alain Mérieux, is a personal friend of Xi Jinping, & he helped build the P4 lab in Wuhan.
Moderna also happened to have a vaccine ready to go within hours of China publicizing gene sequence for virus. Recall, the bio tech company had ZERO products brought to market prior to its "miracle" mRNA vax receiving emergency approval.
Prior to mRNA vax, Moderna was on its way to becoming the next Theranos. They had billions of $$$ in fundraising thanks to hype, but no functioning products. We are now supposed to believe they solved it in a matter of hours, after a decade of failures.
Even after leaving for Moderna, Bancel continued to serve on the board for Foundation Merieux, the non-profit affiliated with the company.
https://christopherfalcon.substack.com/p/the-french-connection-from-the-wuhan
In 2004 the Chinese contacted the French company bioMerieux owned by Alain Merieux, (who is a personal friend of now dictator Xi Jinping) to design a level 4 bio facility in Wuhan, China as the Chinese had limited experience in designing a level 4 facility. This facility would take a full ten years to come to fruition, but during that time, the now CEO of Moderna was formerly the CEO of bioMerieux (2007-2011) through which time he overseen the design of the now infamous Wuhan lab. It was revealed in August of 2021 that The Wuhan lab had serious ventilation issues as described in the House Foreign Affairs Committee Origins of Covid Report. In September of 2019 the WIV took its virus database off the internet, not long after that the WIV had a contract competition to renovate its air conditioning/ventilation system. The contract ended up being for a total of $606 million, evidence of which the Chinese Ministry of Finance later pulled according to WaPo journalist Josh Rogin. The WIV level 4 lab was inaugurated on January 31, 2015, after being designed by the aforementioned French company, and was built by the Chinese end of that partnership. The question is this: did the Chinese know the French designed a horribly flawed ventilation system that bioMerieux also apparently never finished, or were they just as surprised as the rest of the world? Since the Chinese CDC was at Event 201, it’s hard to say for certain.
Considering that Stephane Bancel, one of the main people involved in the design of the WIV lvl4 lab left the company some three years before the actual construction of the lab does give him some plausible deniability… that is until you think about if for more than thirty seconds. What is the likelihood of Bancel overseeing the design of the WIV level 4 lab, then, leaving bioMerieux to become the CEO of the mRna vaccine company Moderna?
Moderna was perfectly positioned to make billions of dollars through global emergency use authorizations after this illegally U.S. government funded (through Echo Health alliance via NIAID and Fauci according to DARPA documents obtained via a FOIA request) Gain of Function research created the Chimera spike protein which was inserted into the backbone of a Sars Cov virus. Which is why the French, nor the Americans would even entertain the idea of a lab leak, even though they all knew once the scientific community figured out the covid19 genetic sequence. A Novel virus, indeed.
The strange saga of how France helped build Wuhan's top-security virus lab - The maximum-level biosafety laboratory at the Wuhan Institute of Virology was the first of its kind to be built in China, and has been the centre of huge speculation since the start of the Covid-19 pandemic which originated in that city.
The laboratory, which is equipped to handle Class 4 pathogens (P4) including dangerous viruses such as Ebola, was built with the help of French experts and under the guidance of French billionaire businessman Alain Mérieux, despite strong objections by health and defence officials in Paris.
Since the laboratory's inauguration by prime minister Bernard Cazeneuve in 2017, however, France has had no supervisory role in the running of the facility and planned cooperation between French researchers and the laboratory has come to a grinding halt.
But as more trials get underway, Moderna is gingerly opening up. The company agreed to Science's request for access to some of its researchers and labs over the past few months. And last month, at the annual J.P. Morgan Healthcare Conference in San Francisco, California, CEO Stéphane Bancel unveiled Moderna's first round of drug candidates, which include vaccines for Zika and flu, and a therapy for heart failure.
Expectations are high. Being a startup valued at more than a billion dollars—an anomaly that venture capitalists dub a unicorn—comes with scrutiny, and many wonder whether Moderna's pipeline, consisting mostly of vaccines for now, will expand to match the company's original vision of mRNA as a broad treatment platform. "There were a lot of really big promises made," says Jason Schrum, a biotechnology consultant in San Francisco and a former Moderna employee. "That's what people latched onto; they want the promises to be true, and they want to see the investment really turn it into something meaningful."
https://twitter.com/pc_432/status/1338265436685680642
https://nitter.net/pc_432/status/1338265436685680642
http://www.china.org.cn/china/special_coverage/2018-12/19/content_74290838.htm
https://twitter.com/mista98berk/status/1725991330239672797
https://nitter.net/mista98berk/status/1725991330239672797
Stéphane Bancel, CEO of Moderna, was previously CEO of Bio-Mérieux whose owner, Alain Mérieux, friend of Xi Jinping, financed the P4 laboratory in Wuhan.
https://twitter.com/JordanSchachtel/status/1397253077464461316
https://nitter.net/JordanSchachtel/status/1397253077464461316
(for more links read the full thread)
File this under shocking connections worth further exploration: Moderna CEO Stéphane Bancel (now a billionaire equity shareholder) was previously CEO of bioMérieux. bioMérieux's founder, Alain Mérieux, is a personal friend of Xi Jinping, & he helped build the P4 lab in Wuhan.
Moderna also happened to have a vaccine ready to go within hours of China publicizing gene sequence for virus. Recall, the bio tech company had ZERO products brought to market prior to its "miracle" mRNA vax receiving emergency approval.
Prior to mRNA vax, Moderna was on its way to becoming the next Theranos. They had billions of $$$ in fundraising thanks to hype, but no functioning products. We are now supposed to believe they solved it in a matter of hours, after a decade of failures.
Even after leaving for Moderna, Bancel continued to serve on the board for Foundation Merieux, the non-profit affiliated with the company.
The strange saga of how France helped build Wuhan's top-security virus lab - The maximum-level biosafety laboratory at the Wuhan Institute of Virology was the first of its kind to be built in China, and has been the centre of huge speculation since the start of the Covid-19 pandemic which originated in that city.
The laboratory, which is equipped to handle Class 4 pathogens (P4) including dangerous viruses such as Ebola, was built with the help of French experts and under the guidance of French billionaire businessman Alain Mérieux, despite strong objections by health and defence officials in Paris.
Since the laboratory's inauguration by prime minister Bernard Cazeneuve in 2017, however, France has had no supervisory role in the running of the facility and planned cooperation between French researchers and the laboratory has come to a grinding halt.
But as more trials get underway, Moderna is gingerly opening up. The company agreed to Science's request for access to some of its researchers and labs over the past few months. And last month, at the annual J.P. Morgan Healthcare Conference in San Francisco, California, CEO Stéphane Bancel unveiled Moderna's first round of drug candidates, which include vaccines for Zika and flu, and a therapy for heart failure.
Expectations are high. Being a startup valued at more than a billion dollars—an anomaly that venture capitalists dub a unicorn—comes with scrutiny, and many wonder whether Moderna's pipeline, consisting mostly of vaccines for now, will expand to match the company's original vision of mRNA as a broad treatment platform. "There were a lot of really big promises made," says Jason Schrum, a biotechnology consultant in San Francisco and a former Moderna employee. "That's what people latched onto; they want the promises to be true, and they want to see the investment really turn it into something meaningful."
https://twitter.com/pc_432/status/1338265436685680642
http://www.china.org.cn/china/special_coverage/2018-12/19/content_74290838.htm
https://twitter.com/mista98berk/status/1725991330239672797
https://nitter.net/mista98berk/status/1725991330239672797
Stéphane Bancel, CEO of Moderna, was previously CEO of Bio-Mérieux whose owner, Alain Mérieux, friend of Xi Jinping, financed the P4 laboratory in Wuhan.
The strange saga of how France helped build Wuhan's top-security virus lab - The maximum-level biosafety laboratory at the Wuhan Institute of Virology was the first of its kind to be built in China, and has been the centre of huge speculation since the start of the Covid-19 pandemic which originated in that city.
The laboratory, which is equipped to handle Class 4 pathogens (P4) including dangerous viruses such as Ebola, was built with the help of French experts and under the guidance of French billionaire businessman Alain Mérieux, despite strong objections by health and defence officials in Paris.
Since the laboratory's inauguration by prime minister Bernard Cazeneuve in 2017, however, France has had no supervisory role in the running of the facility and planned cooperation between French researchers and the laboratory has come to a grinding halt.
But as more trials get underway, Moderna is gingerly opening up. The company agreed to Science's request for access to some of its researchers and labs over the past few months. And last month, at the annual J.P. Morgan Healthcare Conference in San Francisco, California, CEO Stéphane Bancel unveiled Moderna's first round of drug candidates, which include vaccines for Zika and flu, and a therapy for heart failure.
Expectations are high. Being a startup valued at more than a billion dollars—an anomaly that venture capitalists dub a unicorn—comes with scrutiny, and many wonder whether Moderna's pipeline, consisting mostly of vaccines for now, will expand to match the company's original vision of mRNA as a broad treatment platform. "There were a lot of really big promises made," says Jason Schrum, a biotechnology consultant in San Francisco and a former Moderna employee. "That's what people latched onto; they want the promises to be true, and they want to see the investment really turn it into something meaningful."
https://twitter.com/pc_432/status/1338265436685680642
http://www.china.org.cn/china/special_coverage/2018-12/19/content_74290838.htm